Dr. Susanibar on Important Considerations When Treating Multiple Myeloma
Sandra P. Susanibar-Adaniya, MD, discusses important considerations when treating patients with multiple myeloma.
Dr. Susanibar-Adaniya on the Impact of the MAIA and GRIFFIN Trials in Multiple Myeloma Treatment
Sandra P. Susanibar-Adaniya, MD, discusses 2 key trials in multiple myeloma that improved the treatment landscape for transplant-eligible and ineligible patients.
Dr. Susanibar-Adaniya on the Standard of Care for Patients With Newly Diagnosed Multiple Myeloma
Sandra P. Susanibar-Adaniya, MD, discusses the current standard of care for patients with newly diagnosed multiple myeloma.
Dr. Susanibar-Adaniya on the Evolution of Combination Therapies in Multiple Myeloma
Sandra P. Susanibar-Adaniya, MD, discusses how advancements in triplet therapy have shifted the treatment paradigm for patients with newly diagnosed, transplant-ineligible multiple myeloma.
Immunotherapy Must Become More Precise and Personalized in Lung Cancer
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Is There a Potential Role for Rapcabtagene Autoleucel in R/R LBCL?
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
2 Clarke Drive Cranbury, NJ 08512